NucleoTech Establishes Direct In Vivo Discovery Engine
A major milestone enabling rapid and reliable identification of next-generation brain shuttles, supporting the development of shuttle-enabled therapeutics.
March 9, 2026
NucleoTech Receives Letter of Support from Leading Japanese CNS Pharma
April 5, 2026
NucleoTech Lead Carrier Demonstrates Preliminary Results Exceeding Commercial TfR Benchmark